At Shattuck Labs, we are pioneering a new class of dual function fusion proteins to create novel therapeutics for patients with cancer and autoimmune disease.
Shattuck was founded in 2016 with the goal of building a fully integrated biotechnology company that creates novel therapeutics for the treatment of cancer and autoimmune disease. At the core of that vision was creating a company that brings together leading scientists, drug manufacturers, physicians, and other professionals to challenge conventional thinking and develop transformational medicines that measurably improve the lives of our patients.
One of the truly differentiating aspects of Shattuck has been the novelty of our proprietary Agonist Redirected Checkpoint (ARC) platform technology. Combining a strong technological foundation with deep professional expertise has allowed us to deliver on our broader corporate mission. Demonstrating our sense of urgency, we were able to bring our first compound to the clinic within two years of founding the company.
With over 400 ARC compounds produced to date, Shattuck’s research and discovery engine has yielded enormous results. Our discovery production is a cornerstone of all that we do, and we have invested heavily in understanding the science behind all of our compounds. As a result of the significant investment in our platform, we are able to move compounds from bench to clinic in fewer than 18 months, well ahead of industry-standard timelines.
Today we have two product candidates in global clinical trials, treating patients with a high unmet need in cancer. Our constant pursuit of excellence continues to drive us to build a company at the helm of providing truly breakthrough medicines for patients in need.
A message from Josiah Hornblower, Co-founder, CEO from 2016-2020
Shattuck Labs was born out of deep friendship, a mutual passion for science, and a radical goal of redesigning cancer medicines to improve human health. My co-founder Taylor Schreiber and I became friends a few years after college, when I was pursuing a finance career in New York and he was working in a research lab in Boston. We initially bonded through our common high-school experience at St. Paul’s School in Concord, NH, where I graduated several years before him. Our friendship evolved during Taylor’s MD/Ph.D. training, when we would have long conversations about cutting-edge technologies that could positively change the world.
Eventually, our divergent career paths merged through a series of collaborative biotechnology ventures. Each chapter in this odyssey of building biotech companies has informed our present vision of what our company should be. Shattuck Labs was established in May 2016 and named after George Shattuck, a young, visionary medical doctor who founded our high school in 1856. His legacy gave me and Taylor a common bond and experience that ultimately brought forth the company we have built today. We feel very privileged to see Shattuck grow, evolve, and succeed with the help of our amazing colleagues. In early 2020 Taylor took over as CEO, and our partnership continues. Shattuck is now at the nexus of recent advances in the targets that benefit cancer patients, as well as the tools required to engage those targets. I could not be more excited to help our team write the next chapter in Shattuck’s story.
Mission & Vision
Our vision is to build incredible medicines off the beaten path, by challenging ourselves to think differently.
We work with a sense of urgency, focused on scientific excellence and thoughtful stewardship of resources, to translate innovative ideas into medicines that improve the lives of patients with serious diseases.